The European Patent Office (EPO) has granted patent EP3688015B1, titled "MUTATED ADENO-ASSOCIATED VIRAL CAPSID PROTEINS FOR CHEMICAL COUPLING OF LIGANDS, NANOPARTICLES OR DRUGS VIA THIOETHER BINDING AND PRODUCTION METHOD THEREOF." The patent, effective March 18, 2026, covers specific mutated adeno-associated viral capsid proteins and their production methods, focusing on applications in chemical coupling via thioether binding.

This patent grant signifies a new intellectual property right in the field of biotechnology and drug delivery. Companies operating in this space, particularly those involved in gene therapy, nanoparticle drug delivery, or viral vector development, should review the patent's claims to ensure their activities do not infringe. While this is a patent grant and not a regulatory rule with direct compliance obligations for all entities, it establishes exclusive rights that may impact research, development, and commercialization strategies.